NCT06618664

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study of Anti CTLA-4 Antibody SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 590 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab combined with Bevacizumab for the first-line treatment of advanced HCC

Conditions

• Advanced Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	SHR-8068	SHR-8068: injection, 50 mg/10 mL, intravenous infusion
DRUG	Adebrelimab	Adebrelimab: injection, 600 mg/12 mL, intravenous infusion
DRUG	Bevacizumab	Bevacizumab: injection, 100 mg/4 mL, intravenous infusion
DRUG	Sintilimab	Sintilimab: injection, 100 mg/10 mL, intravenous infusion

Timeline

• Start date: 2024-10-28
• Primary completion: 2026-03-31
• Completion: 2030-12-31
• First posted: 2024-10-01
• Last updated: 2025-05-15

Locations

1 site across 1 country: China